Hemanext Inc. Announces New HCPCS Code for “Red Blood Cells, Leukocytes Reduced, Oxygen/Carbon Dioxide Reduced, Each Unit”
The Centers for Medicare & Medicaid Services (CMS) has officially issued a new Healthcare Common Procedure Coding System (HCPCS) code for “Red blood cells, leukocytes reduced, oxygen/carbon dioxide reduced, each unit,” an innovative blood transfusion product produced by the Hemanext ONE Red Blood Cell Processing and Storage System. - September 09, 2024
Hemanext Inc. Announces Completion of Cancer and Burn Safety Study, a Significant Milestone for the Hemanext ONE® Innovative Red Blood Cell Processing and Storage System
The post-market clinical study in Bergen, Norway, that was designed to assess the safety of transfusing hypoxic red blood cells (RBCs) in patients with acute burns and hematological malignancies, has been completed. - August 20, 2024
Hemanext Inc. Announces Significant Milestone with FDA Marketing Authorization for Hemanext ONE®, Hemanext’s Innovative Red Blood Cell (RBC) Processing and Storage System
Hemanext ONE has been granted marketing authorization for commercial distribution via the De Novo process by the U.S. Food and Drug Administration (FDA). - September 21, 2023
Hemanext Announces Founder Martin Cannon's Retirement, Appoints Andrew Dunham as CEO, and Raises Funding for Growth
Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, marks a significant turning point in its history as the company announces the retirement of its founder, Martin Cannon. Simultaneously, the Hemanext Board of Directors has appointed Andrew Dunham, the... - September 18, 2023
Hemanext Announces Membership in European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, today announced its membership in the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), the region's premier trade association for small to medium-sized companies in the pharmaceutical,... - July 05, 2023
Hemanext Announces a Strategic Partnership and Investment from Vitalant
Partnership to include research and development at Vitalant Innovation Center. - June 07, 2023
Hemanext Continues European Rollout of Hemanext ONE® RBC Processing and Storage System
Groundbreaking technology to be deployed to transfuse thalassemia patients in Italy and acute bleeding burn patients in Norway. - May 25, 2023
Hemanext Partners with Sickle Cell Disease Association of America and OneBlood to Support Blood Drive in Miami Gardens
NFL Linebacker Markus Golden Joins Forces for an Inspiring #Donate4Diversity Blood Drive on Saturday, April 1, 2023, at Walmart Supercenter Parking Lot, 19501 NW 27th Ave., Miami Gardens, FL - March 30, 2023
Hemanext Partners with the Miami Chapter of the Sickle Cell Disease Association of America to Support Local Sickle Cell Disease Community
Partnership Will Expand to Include Educational and Donation Event with OneBlood. - January 17, 2023
Hemanext Announces Publication of Hypoxic Blood Storage Study in Blood Advances
Research shows that hypoxic storage preserves faster oxygen unloading from red blood cells compared to standard conditions. - August 05, 2022
Hemanext Announces Appointment of Daan Kok as the Executive Vice President & General Manager of Hemanext for Europe, Middle East, and Africa
Hemanext Inc. (“Hemanext” or the “Company”), a leading innovator in blood processing and storage technology, today announced the appointment of Daan Kok as the Executive Vice President & General Manager of Hemanext for Europe, Middle East and Africa (EMEA). In his role,... - July 05, 2022
Hemanext to Present New Red Blood Cell Research Data at AABB 2020
Four abstracts add to the growing body of evidence supporting hypoxic storage of RBCs. - September 29, 2020
Thalassaemia International Federation and Hemanext® Inc. Announce New Strategic Alliance
Organizations create partnership to support the needs of people living with hemoglobin disorders. - June 11, 2020